Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb 16:22:516-21.
doi: 10.12659/msm.897179.

Prognostic Value of Protocadherin10 (PCDH10) Methylation in Serum of Prostate Cancer Patients

Qiu-Kui Deng  1 , Yong-Gang Lei  2 , Ying-Li Lin  3 , Jian-Guo Ma  4 , Wen-Ping Li  4
Affiliations

Prognostic Value of Protocadherin10 (PCDH10) Methylation in Serum of Prostate Cancer Patients

Qiu-Kui Deng et al. Med Sci Monit. .

Abstract

BACKGROUND Prostate cancer is a heterogeneous malignancy with outcome difficult to predict. Currently, there is an urgent need to identify novel biomarkers that can accurately predict patient outcome and improve the treatment strategy. The aim of this study was to investigate the methylation status of PCDH10 in serum of prostate cancer patients and its potential relevance to clinicopathological features and prognosis. MATERIAL AND METHODS The methylation status of PCDH10 in serum of 171 primary prostate cancer patients and 65 controls was evaluated by methylation-specific PCR (MSP), after which the relationship between PCDH10 methylation and clinicopathologic features was evaluated. Kaplan-Meier survival analysis and Cox analysis were used to evaluate the correlation between PCDH10 methylation and prognosis. RESULTS PCDH10 methylation occurred frequently in serum of prostate cancer patients. Moreover, PCDH10 methylation was significantly associated with higher preoperative PSA level, advanced clinical stage, higher Gleason score, lymph node metastasis, and biochemical recurrence (BCR). In addition, patients with methylated PCDH10 had shorter BCR-free survival and overall survival than patients with unmethylated PCDH10. Univariate and multivariate Cox proportional hazards model analysis indicated that PCDH10 methylation in serum is an independent predictor of worse BCR-free survival and overall survival. CONCLUSIONS PCDH10 methylation in serum is a potential prognostic biomarker for prostate cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Representative MSP results for PCDH10 methylation in serum of patients with prostate cancer. A – methylation-positive control; B – unmethylation-positive control; T – prostate cancer patients; T71 and 73 – exhibited methylated PCDH10; T72 – exhibited unmethylated PCDH10.
Figure 2
Figure 2
Associations between PCDH10 methylation and BCR-free survival of patients after radical prostatectomy. Patients with methylated PCDH10 showed significantly shorter BCR-free survival than those with unmethylated PCDH10. (P<0.001, log-rank test)
Figure 3
Figure 3
Associations between PCDH10 methylation and overall survival of patients after radical prostatectomy. Patients with methylated PCDH10 showed significantly shorter overall survival than those with unmethylated PCDH10. (P=0.001, log-rank test).
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. Cancer J Clin. 2015;65(1):5–29. - PubMed
    1. Wilkins A, Dearnaley D, Somaiah N. Genomic and histopathological tissue biomarkers that predict radiotherapy response in localised prostate cancer. Biomed Res Int. 2015;2015:238757. - PMC - PubMed
    1. Roussel B, Ouellet GM, Mohile SG, et al. Prostate cancer in elderly men: Screening, active surveillance, and definitive therapy. Clin Geriatr Med. 2015;31(4):615–29. - PubMed
    1. Kim JH, Hong SK. Potential utility of novel biomarkers in active surveillance of low-risk prostate cancer. Biomed Res Int. 2015;2015:475920. - PMC - PubMed
    1. Hung AY, Levy L, Kuban DA. Stage T1c prostate cancer: A heterogeneous category with widely varying prognosis. Cancer J. 2002;8(6):440–44. - PubMed

Publication types